Edison Issues Outlook on ReNeuron Group (RENE)

Author's Avatar
Aug 26, 2020
Article's Main Image

LONDON, UK / ACCESSWIRE / August 26, 2020 / ReNeuron has refocussed onto its human retinal progenitor cell (hRPC) as shown in the last business update and in the FY20 results. hRPC, now the lead project, show a consistent and robust sustained averaged response at the one million cell dose. The next dose level, two million cells in nine patients, could start this autumn. A pivotal study could be initiated in 2022. ReNeuron is starting to create multiple partnering opportunities from its core technologies. We have revised our valuation to £170m from £107m.